182 related articles for article (PubMed ID: 18022385)
1. Effects of PAX3-FKHR on malignant phenotypes in alveolar rhabdomyosarcoma.
Kikuchi K; Tsuchiya K; Otabe O; Gotoh T; Tamura S; Katsumi Y; Yagyu S; Tsubai-Shimizu S; Miyachi M; Iehara T; Hosoi H
Biochem Biophys Res Commun; 2008 Jan; 365(3):568-74. PubMed ID: 18022385
[TBL] [Abstract][Full Text] [Related]
2. Alveolar rhabdomyosarcoma: is the cell of origin a mesenchymal stem cell?
Charytonowicz E; Cordon-Cardo C; Matushansky I; Ziman M
Cancer Lett; 2009 Jul; 279(2):126-36. PubMed ID: 19008039
[TBL] [Abstract][Full Text] [Related]
3. Structural and functional studies of FKHR-PAX3, a reciprocal fusion gene of the t(2;13) chromosomal translocation in alveolar rhabdomyosarcoma.
Hu Q; Yuan Y; Wang C
PLoS One; 2013; 8(6):e68065. PubMed ID: 23799156
[TBL] [Abstract][Full Text] [Related]
4. Up-regulation of MET but not neural cell adhesion molecule expression by the PAX3-FKHR fusion protein in alveolar rhabdomyosarcoma.
Ginsberg JP; Davis RJ; Bennicelli JL; Nauta LE; Barr FG
Cancer Res; 1998 Aug; 58(16):3542-6. PubMed ID: 9721857
[TBL] [Abstract][Full Text] [Related]
5. Adult cutaneous alveolar rhabdomyosarcoma on the face diagnosed by the expression of PAX3-FKHR gene fusion transcripts.
Nakagawa N; Tsuda T; Yamamoto M; Ito T; Futani H; Yamanishi K
J Dermatol; 2008 Jul; 35(7):462-7. PubMed ID: 18705836
[TBL] [Abstract][Full Text] [Related]
6. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma.
Taulli R; Scuoppo C; Bersani F; Accornero P; Forni PE; Miretti S; Grinza A; Allegra P; Schmitt-Ney M; Crepaldi T; Ponzetto C
Cancer Res; 2006 May; 66(9):4742-9. PubMed ID: 16651427
[TBL] [Abstract][Full Text] [Related]
7. AKT and PAX3-FKHR cooperation enforces myogenic differentiation blockade in alveolar rhabdomyosarcoma cell.
Jothi M; Nishijo K; Keller C; Mal AK
Cell Cycle; 2012 Mar; 11(5):895-908. PubMed ID: 22333587
[TBL] [Abstract][Full Text] [Related]
8. The oncogenic transcription factor PAX3-FKHR can convert fibroblasts into contractile myotubes.
Scuoppo C; Riess I; Schmitt-Ney M; Allegra P; Forni PE; Bersani F; Taulli R; Accornero P; Crepaldi T; Ponzetto C
Exp Cell Res; 2007 Jul; 313(11):2308-17. PubMed ID: 17490646
[TBL] [Abstract][Full Text] [Related]
9. Nephroblastoma overexpressed (NOV/CCN3) gene: a paired-domain-specific PAX3-FKHR transcription target that promotes survival and motility in alveolar rhabdomyosarcoma cells.
Zhang Y; Wang C
Oncogene; 2011 Aug; 30(32):3549-62. PubMed ID: 21423212
[TBL] [Abstract][Full Text] [Related]
10. PAX-FKHR function as pangenes by simultaneously inducing and inhibiting myogenesis.
Graf Finckenstein F; Shahbazian V; Davicioni E; Ren YX; Anderson MJ
Oncogene; 2008 Mar; 27(14):2004-14. PubMed ID: 17922034
[TBL] [Abstract][Full Text] [Related]
11. The role of chimeric paired box transcription factors in the pathogenesis of pediatric rhabdomysarcoma.
Barr FG
Cancer Res; 1999 Apr; 59(7 Suppl):1711s-1715s. PubMed ID: 10197585
[TBL] [Abstract][Full Text] [Related]
12. Identification of PAX3-FKHR-regulated genes differentially expressed between alveolar and embryonal rhabdomyosarcoma: focus on MYCN as a biologically relevant target.
Mercado GE; Xia SJ; Zhang C; Ahn EH; Gustafson DM; Laé M; Ladanyi M; Barr FG
Genes Chromosomes Cancer; 2008 Jun; 47(6):510-20. PubMed ID: 18335505
[TBL] [Abstract][Full Text] [Related]
13. Carnitine palmitoyltransferase 1A (CPT1A): a transcriptional target of PAX3-FKHR and mediates PAX3-FKHR-dependent motility in alveolar rhabdomyosarcoma cells.
Liu L; Wang YD; Wu J; Cui J; Chen T
BMC Cancer; 2012 Apr; 12():154. PubMed ID: 22533991
[TBL] [Abstract][Full Text] [Related]
14. PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma.
Hanna JA; Garcia MR; Lardennois A; Leavey PJ; Maglic D; Fagnan A; Go JC; Roach J; Wang YD; Finkelstein D; Hatley ME
Oncogene; 2018 Apr; 37(15):1991-2007. PubMed ID: 29367756
[TBL] [Abstract][Full Text] [Related]
15. PAX7-FKHR fusion gene inhibits myogenic differentiation via NF-kappaB upregulation.
Charytonowicz E; Matushansky I; Doménech JD; Castillo-Martín M; Ladanyi M; Cordon-Cardo C; Ziman M
Clin Transl Oncol; 2012 Mar; 14(3):197-206. PubMed ID: 22374423
[TBL] [Abstract][Full Text] [Related]
16. Defining the cooperative genetic changes that temporally drive alveolar rhabdomyosarcoma.
Naini S; Etheridge KT; Adam SJ; Qualman SJ; Bentley RC; Counter CM; Linardic CM
Cancer Res; 2008 Dec; 68(23):9583-8. PubMed ID: 19047133
[TBL] [Abstract][Full Text] [Related]
17. Alveolar rhabdomyosarcoma: morphoproteomics and personalized tumor graft testing further define the biology of PAX3-FKHR(FOXO1) subtype and provide targeted therapeutic options.
Brown RE; Buryanek J; Katz AM; Paz K; Wolff JE
Oncotarget; 2016 Jul; 7(29):46263-46272. PubMed ID: 27323832
[TBL] [Abstract][Full Text] [Related]
18. Mouse mesenchymal stem cells expressing PAX-FKHR form alveolar rhabdomyosarcomas by cooperating with secondary mutations.
Ren YX; Finckenstein FG; Abdueva DA; Shahbazian V; Chung B; Weinberg KI; Triche TJ; Shimada H; Anderson MJ
Cancer Res; 2008 Aug; 68(16):6587-97. PubMed ID: 18701482
[TBL] [Abstract][Full Text] [Related]
19. Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas.
Davicioni E; Finckenstein FG; Shahbazian V; Buckley JD; Triche TJ; Anderson MJ
Cancer Res; 2006 Jul; 66(14):6936-46. PubMed ID: 16849537
[TBL] [Abstract][Full Text] [Related]
20. High expression of the PAX3-FKHR oncoprotein is required to promote tumorigenesis of human myoblasts.
Xia SJ; Holder DD; Pawel BR; Zhang C; Barr FG
Am J Pathol; 2009 Dec; 175(6):2600-8. PubMed ID: 19893043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
